This email regarding Doptelet®▼ (avatrombopag) is intended for UK healthcare professionals only and contains promotional content. Click here for Prescribing Information. Adverse Event reporting can be found at the bottom of this email. Problems viewing this email? | View it in your browser Updates in Primary Chronic Immune Thrombocytopenia (ITP): Shared decision-making in primary chronic ITP Doptelet®▼(avatrombopag) is indicated for the treatment of primary chronic ITP in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1 Treatment should be initiated by and remain under the supervision of a physician who is experienced in the treatment of haematological diseases.1 A key part of providing personalised care is shared decision-making.2–4 Collaborating with your primary chronic ITP patients on decisions surrounding their care is recommended by international guidelines and offers benefits for both you and your patients.2-5 Benefits for patients Better understanding of treatment options5 Increased treatment adherence5,6 Improvement in confidence and coping skills5 Benefits for clinicians Improvement in health behaviours from patients5 Increased staff morale6 Greater patient satisfaction6 By asking a few simple questions, you can prompt your patients to express their preferences and reach a decision about their care based on what matters to them.2 Questions for conversations with your chronic ITP patients are in resources available here (Clicking this link will take you to promotional information, initiated and funded by Sobi) When speaking to your primary chronic ITP patients, consider which TPO‑RA characteristics best fit their lives.1,7,8 In the TRAPeze study, among 32 adult patients in the UK and Ireland who had been treated with eltrombopag or romiplostin (the only TPO-RAs available at the time of the study), method of administration and food interactions were the strongest drivers of patient preference.9 Doptelet should be taken with food. 7x more likely to choose oral treatment vs injection9 4x more likely to choose oral treatment with no food‑type restrictions vs those with restrictions9 Learn more about the results from TRAPeze (Clicking this link will take you to promotional information, initiated and funded by Sobi) Abbreviations: ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist. References: 1. Doptelet EMC Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/11837/smpc (Accessed January 2024). This link will take you to a third-party website. 2. National Institute for Health and Care Excellence. Shared decision making. Guideline NG197. Available at: https://www.nice.org.uk/guidance/ng197/chapter/recommendations (Accessed January 2024). This link will take you to a third-party website. 3. Neunert C, et al. Blood Adv. 2019;3(23):3829–3866. 4. Provan D, et al. Blood Adv. 2019;3(22):3780–3817. 5. The Kings Fund. Making shared decision-making a reality: No decision about me, without me. Available at: https://www.kingsfund.org.uk/publications/making-shared-decision-making-reality (Accessed January 2024). This link will take you to a third-party website. 6. The Health Foundation. Person-centred care made simple. Available at: https://www.health.org.uk/sites/default/files/PersonCentredCareMadeSimple_0.pdf (Accessed January 2024). This link will take you to a third-party website. 7. Eltrombopag EMA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/revolade (Accessed January 2024). This link will take you to a third-party website. 8. Romiplostim EMA Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/nplate (Accessed January 2024). 9. McDonald V, et al. Hematology.2021;26(1):799–808. ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at medical.info.uk@sobi.com or Telephone +44 (0) 800 111 4754 Click here for Prescribing Information © 2023 Swedish Orphan Biovitrum Ltd – All rights reserved. Sobi and Doptelet are trademarks of Swedish Orphan Biovitrum Ltd, Suite 2, Riverside 3, Granta Park, Great Abington, Cambridgeshire, CB21 6AD. www.sobi.com/uk/en Job code: PP‑19903 © SOBI Ltd 2023 January 2024 This email has been forwarded to you by Data4NHS, on behalf of Sobi. Manage your Data4NHS profile by submitting your changes HERE. View our privacy policy HERE. UNSUBSCRIBE.